Inotiv, Inc. (NOTVQ) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Inotiv, Inc. (NOTVQ) has a cash flow conversion efficiency ratio of -0.014x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-1.07 Million) by net assets ($77.10 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Review NOTVQ financial flexibility score to assess the company's free cash flow relative to its total liabilities.
Inotiv, Inc. - Cash Flow Conversion Efficiency Trend (1997–2025)
This chart illustrates how Inotiv, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see market value of Inotiv, Inc. for the company's overall valuation and market capitalisation.
Inotiv, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Inotiv, Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
HODL SPAC EUROPE AB
F:NW1
|
0.039x |
|
Chelverton UK Dividend Trust PLC
LSE:SDV
|
0.022x |
|
Anexo Group Plc
LSE:ANX
|
-0.057x |
|
Bezant Resources Plc
LSE:BZT
|
-0.071x |
|
GRIT Real Estate Income Group
LSE:GR1T
|
0.058x |
|
Hemogenyx Pharmaceuticals PLC
LSE:HEMO
|
3.264x |
|
ONETECH SOLUTIONS HOLDINGS BERHAD
KLSE:03041
|
-0.145x |
|
Valion Bio Inc
NASDAQ:VBIO
|
-0.136x |
Annual Cash Flow Conversion Efficiency for Inotiv, Inc. (1997–2025)
The table below shows the annual cash flow conversion efficiency of Inotiv, Inc. from 1997 to 2025. View Inotiv, Inc. share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-09-30 | $136.03 Million | $-10.46 Million | -0.077x | -92.58% |
| 2024-09-30 | $170.50 Million | $-6.80 Million | -0.040x | -138.43% |
| 2023-09-30 | $268.49 Million | $27.88 Million | 0.104x | +816.16% |
| 2022-09-30 | $359.77 Million | $-5.22 Million | -0.015x | -114.19% |
| 2021-09-30 | $105.13 Million | $10.75 Million | 0.102x | -39.81% |
| 2020-09-30 | $7.60 Million | $1.29 Million | 0.170x | +2.35% |
| 2019-09-30 | $10.71 Million | $1.78 Million | 0.166x | -48.21% |
| 2018-09-30 | $10.88 Million | $3.49 Million | 0.320x | +119.47% |
| 2017-09-30 | $8.47 Million | $1.24 Million | 0.146x | +2.71% |
| 2016-09-30 | $7.46 Million | $1.06 Million | 0.142x | -25.00% |
| 2015-09-30 | $10.72 Million | $2.03 Million | 0.189x | +7.31% |
| 2014-09-30 | $9.54 Million | $1.68 Million | 0.177x | +9.97% |
| 2013-09-30 | $9.46 Million | $1.52 Million | 0.161x | +870.02% |
| 2012-09-30 | $9.59 Million | $-200.00K | -0.021x | -129.88% |
| 2011-09-30 | $15.59 Million | $1.09 Million | 0.070x | -69.50% |
| 2010-09-30 | $10.67 Million | $2.44 Million | 0.229x | +16.05% |
| 2009-09-30 | $13.12 Million | $2.59 Million | 0.197x | +486.76% |
| 2008-09-30 | $17.80 Million | $598.00K | 0.034x | -78.71% |
| 2007-09-30 | $18.55 Million | $2.93 Million | 0.158x | -28.76% |
| 2006-09-30 | $17.35 Million | $3.84 Million | 0.222x | +902.04% |
| 2005-09-30 | $19.60 Million | $-541.25K | -0.028x | -118.93% |
| 2004-09-30 | $19.42 Million | $2.83 Million | 0.146x | -2.26% |
| 2003-09-30 | $19.73 Million | $2.95 Million | 0.149x | +38.82% |
| 2002-09-30 | $18.90 Million | $2.03 Million | 0.108x | -52.39% |
| 2001-09-30 | $17.83 Million | $4.03 Million | 0.226x | +772.94% |
| 2000-09-30 | $16.06 Million | $-539.16K | -0.034x | -136.51% |
| 1999-09-30 | $17.40 Million | $1.60 Million | 0.092x | -35.63% |
| 1998-09-30 | $16.80 Million | $2.40 Million | 0.143x | +23.21% |
| 1997-09-30 | $6.90 Million | $800.00K | 0.116x | -- |
About Inotiv, Inc.
Inotiv, Inc. provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries in the United States, the Netherlands, and internationally. The company operates through two segments, Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). The DMS segment manufactures scientific instruments for life sciences researc… Read more